Loading clinical trials...
Loading clinical trials...
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema (KINGFISHER)
Conditions
Interventions
Brolucizumab
Aflibercept
Locations
92
United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Phoenix, Arizona, United States
Novartis Investigative Site
Tucson, Arizona, United States
Novartis Investigative Site
Beverly Hills, California, United States
Novartis Investigative Site
Campbell, California, United States
Novartis Investigative Site
Fresno, California, United States
Start Date
July 17, 2019
Primary Completion Date
March 24, 2021
Completion Date
March 24, 2021
Last Updated
August 12, 2022
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT06701721
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions